Cytokines News and Research

Latest Cytokines News and Research

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a Phase 1 clinical trial evaluating IMO-2125, a novel immune modulator, in null-responder patients with chronic hepatitis C virus (HCV) infection.

1 Nov 2010

Idera presents data on TLR 3 agonist as vaccine adjuvants at Immunological Meeting

Idera Pharmaceuticals, Inc. today announced a presentation describing the chemistry and immunological activity of its proprietary Toll-Like Receptor (TLR) 3 agonist compounds and the use of these compounds as vaccine adjuvants in a preclinical model.

30 Oct 2010

New findings on Th17 cells pave way for human cancer treatment protocol

A recently identified immune cell that directs other cells to fight infection plays a critical role in regulating the immune system in both health and disease. Researchers from the University of Pennsylvania School of Medicine have discovered how a stimulatory molecule and a protein found on the membrane of another immune cell make T helper 17 cells multi-taskers of sorts. Th17 cells protect the body against infection and cancer, but are also culprits in some autoimmune diseases and out-of-control, cancerous cell growth.

29 Oct 2010

Metagenics awarded two new patents for hops-derived anti-inflammatory compositions

Metagenics, Inc. has been awarded two new patents for discoveries relating to its research on the anti-inflammatory properties of reduced iso-alpha acids (RIAA) derived from hops. Metagenics is a life sciences company focused on reversing chronic illness and improving health through therapeutic nutrition and lifestyle changes. The discoveries were made by researchers at Metagenics’ wholly-owned biotechnology subsidiary, MetaProteomics® LLC.

28 Oct 2010

Immune system may play a role in cancer therapies: Study

The immune system may play a critical role in ensuring the success of certain types of cancer therapies, according to a new study by researchers at the Stanford University School of Medicine. The research showed treatments that disable cancer-promoting genes called oncogenes are much more successful in eradicating tumors in the presence of a signaling molecule secreted by kind of immune cell called a T helper cell.

28 Oct 2010

Idera announces IMO-3100 Phase 1 clinical trial results for autoimmune disease

Idera Pharmaceuticals, Inc. today announced results from its single-dose, dose-escalation Phase 1 clinical trial evaluating the safety and mechanism of action of IMO-3100, its lead Toll-like Receptor (TLR) 7 and TLR9 antagonist drug candidate for the treatment of autoimmune and inflammatory diseases.

22 Oct 2010

Protein IL-37 could help treat inflammatory diseases in adults and children

A husband and wife research team from Melbourne, Australia, have identified a protein that may be a key therapy for many inflammatory diseases, including those affecting premature babies.

21 Oct 2010

An overview on American College of Gastroenterology's Annual Scientific meeting

The association between obesity and gastrointestinal-related cancers and coronary artery disease; the link between an overweight or obese body mass index and the severity of Crohn's disease; and whether inflammatory bowel disease is an independent risk factor for coronary artery disease, were among the highlights of new research that was presented this week at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio.

19 Oct 2010

IBD patients with Vitamin D deficiency at greater risk of osteoporosis, osteopenia

Vitamin D deficiency puts patients with Inflammatory Bowel Disease (IBD) at greater risk of osteoporosis, osteopenia and an overall higher rate of abnormal bone density, according to the results of a new study unveiled today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.

18 Oct 2010

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

15 Oct 2010

Plant compound luteolin reduces age-associated inflammation in brain leading to better cognitive health

A diet rich in the plant compound luteolin reduces age-related inflammation in the brain and related memory deficits by directly inhibiting the release of inflammatory molecules in the brain, researchers report.

14 Oct 2010

ImmunoCellular develops ICT-107 cell-based vaccine for GBM treatment

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it has developed an innovative method for manufacturing the company's lead product candidate, ICT-107, a dendritic cell-based vaccine for the treatment of glioblastoma multiforme (GBM).

13 Oct 2010

Study demonstrates chitosan/IL-12 is an effective anti-tumor immunotherapy

A new study by a University of Arkansas biomedical engineer and his colleagues at the National Cancer Institute demonstrates further promise for chitosan/interleukin-12 as an effective anti-tumor immunotherapy.

13 Oct 2010

Imprime PGG and cetuximab increase overall response rate in metastatic colorectal cancer

A combination of Biothera's Imprime PGG and cetuximab (Erbitux) doubled the overall response rates for second- and third-line metastatic colorectal cancer patients participating in a Phase Ib/IIa clinical trial. The completed trial results were released yesterday at the 35th European Society for Medical Oncology (ESMO) Congress.

13 Oct 2010

Immunomedics receives additional patent claims for antibody therapy

Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that additional claims for the patent family "Method and kit for imaging and treating organs and tissue," were issued as U.S. Patent No. 7,811,570.

13 Oct 2010

BiondVax commences Multimeric-001 flu vaccine Phase IIa clinical study

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, today announced that it has begun to immunize subjects in a Phase IIa clinical trial of the Multimeric-001 Universal Flu Vaccine candidate. The study will evaluate the safety and immunogenicity of the Multimeric-001 vaccine.

11 Oct 2010

Exelixis enters two new collaboration agreements with Bristol-Myers Squibb

Exelixis, Inc. announced today that it has entered into two new collaboration agreements with Bristol-Myers Squibb Company. Under the first agreement, Exelixis will grant to Bristol-Myers Squibb an exclusive license to its small-molecule TGR5 agonist program including backups.

11 Oct 2010

Research may offer new therapy targets for drug-resistant breast tumors

Researchers at the University of Illinois at Chicago College of Medicine have found how gene expression that may contribute to drug resistance is ramped up in unusual types of breast tumors. Their findings may offer new therapy targets.

11 Oct 2010

Childhood abuse may lead to physiological consequences later in life

Seemingly healthy adults, if they were abused or neglected during childhood, may suffer physiological consequences decades later. In research published online last week by the journal Neuropsychopharmacology, a team led by psychiatrists at Brown University and Butler Hospital found that healthy adults who reported being mistreated as kids appear to have an elevated inflammatory response to stress compared to adults who had happier childhoods.

8 Oct 2010

Myrexis to present MPI-0485520 preclinical data at Annual Scientific Meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.

7 Oct 2010